Literature DB >> 8423182

The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients.

R B Cohen1, G V Hahn, J A Tabas, J Peeper, C L Levitz, A Sando, N Sando, M Zasloff, F S Kaplan.   

Abstract

Forty-four patients who had fibrodysplasia ossificans progressiva responded by mail to a questionnaire regarding the age at the onset of heterotopic ossification at fifteen commonly involved anatomical sites. The average age of the patients when they responded to the questionnaire was twenty-seven years (range, three to sixty-nine years). The average age at the onset of ossification was five years (range, birth to twenty-five years). The most common sites of early heterotopic ossification were the neck, spine, and shoulder girdle. Thirty-five (80 per cent) of the patients had had some restrictive heterotopic ossification by the age of seven years. By the age of fifteen years, forty-two (more than 95 per cent) of the patients had severely restricted mobility of the upper limbs. In these patients, heterotopic ossification proceeded in a direction that was axial to appendicular, cranial to caudad, and proximal to distal; this pattern appeared typical for fibrodysplasia ossificans progressiva.

Entities:  

Mesh:

Year:  1993        PMID: 8423182     DOI: 10.2106/00004623-199302000-00008

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  79 in total

1.  Fibrodysplasia ossificans progressiva, a heritable disorder of severe heterotopic ossification, maps to human chromosome 4q27-31.

Authors:  G Feldman; M Li; S Martin; M Urbanek; J A Urtizberea; M Fardeau; M LeMerrer; J M Connor; J Triffitt; R Smith; M Muenke; F S Kaplan; E M Shore
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

2.  Ossifying lesion of the rotator interval.

Authors:  J Pons-Villanueva; L M Romero Muñoz; S Amillo Garayoa
Journal:  Musculoskelet Surg       Date:  2010-12-30

Review 3.  Heterotopic ossification: a review.

Authors:  E F McCarthy; M Sundaram
Journal:  Skeletal Radiol       Date:  2005-08-25       Impact factor: 2.199

4.  Chin-on-chest deformity in patients with fibrodysplasia ossificans progressiva. A case series.

Authors:  Ryan E Moore; John P Dormans; Denis S Drummond; Eileen M Shore; Frederick S Kaplan; Joshua D Auerbach
Journal:  J Bone Joint Surg Am       Date:  2009-06       Impact factor: 5.284

Review 5.  Stem cells and heterotopic ossification: Lessons from animal models.

Authors:  John B Lees-Shepard; David J Goldhamer
Journal:  Bone       Date:  2018-01-31       Impact factor: 4.398

6.  Osteochondromas in fibrodysplasia ossificans progressiva: a widespread trait with a streaking but overlooked appearance when arising at femoral bone end.

Authors:  A Morales-Piga; J Bachiller-Corral; P González-Herranz; M Medrano-SanIldelfonso; J Olmedo-Garzón; G Sánchez-Duffhues
Journal:  Rheumatol Int       Date:  2015-06-07       Impact factor: 2.631

7.  Fibrodysplasia ossificans progressiva without characteristic skeletal anomalies.

Authors:  Hasan Ulusoy
Journal:  Rheumatol Int       Date:  2010-03-27       Impact factor: 2.631

8.  De novo 617G-A nucleotide mutation in the ACVR1 gene in a Taiwanese patient with fibrodysplasia ossificans progressiva.

Authors:  Gau-Tyan Lin; Hsueh-Wei Chang; Chih-Shan Liu; Peng-Ju Huang; Hsien-Chung Wang; Yuh-Min Cheng
Journal:  J Hum Genet       Date:  2006-11-01       Impact factor: 3.172

9.  Early diagnosis of fibrodysplasia ossificans progressiva.

Authors:  Frederick S Kaplan; Meiqi Xu; David L Glaser; Felicity Collins; Michael Connor; Joseph Kitterman; David Sillence; Elaine Zackai; Vardit Ravitsky; Michael Zasloff; Arupa Ganguly; Eileen M Shore
Journal:  Pediatrics       Date:  2008-05       Impact factor: 7.124

10.  Ectopic calcification as discernible manifestation in neonates with pseudohypoparathyroidism type 1a.

Authors:  Masanori Adachi; Koji Muroya; Yumi Asakura; Yoichi Kondoh; Jun Ishihara; Tomonobu Hasegawa
Journal:  Int J Endocrinol       Date:  2009       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.